ABSTRACT
An extract prepared from cranberry juice by dialysis known as nondialyzable material (NDM) has been shown previously to possess anti-adhesion activity toward microbial species including oral bacteria, uropathogenic Escherichia coli and Helicobacter pylori. Bioassay-guided fractionation of cranberry NDM was therefore undertaken to identify the anti-adhesive constituents. An aqueous acetone-soluble fraction (NDMac) obtained from Sephadex LH-20 inhibited adhesion-linked activities by oral bacteria, including co-aggregation of oral bacteria Fusobacterium nucleatum with Streptococcus sanguinis or Porphyromonas gingivalis, and biofilm formation by Streptococcus mutans. Analysis of NDMac and subsequent subfractions by MALDI-TOF MS and 1H NMR revealed the presence of A-type proanthocyanidin oligomers (PACs) of 3-6 degrees of polymerization composed of (epi)catechin units, with some (epi)gallocatechin and anthocyanin units also present, as well as quercetin derivatives. Subfractions containing putative xyloglucans in addition to the mixed polyphenols also inhibit biofilm formation by S. mutans (MIC = 125-250 µg mL-1). These studies suggest that the anti-adhesion activities of cranberry NDM on oral bacteria may arise from a combination of mixed polyphenol and non-polyphenol constituents.
Subject(s)
Bacterial Adhesion/drug effects , Biofilms/drug effects , Fusobacterium nucleatum/drug effects , Mouth/microbiology , Plant Extracts/pharmacology , Porphyromonas gingivalis/drug effects , Streptococcus/drug effects , Vaccinium macrocarpon/chemistry , Fruit and Vegetable Juices/analysis , Fusobacterium nucleatum/physiology , Humans , Plant Extracts/chemistry , Porphyromonas gingivalis/physiology , Streptococcus/physiologyABSTRACT
The link between diet and health has lead to the promotion of functional foods which can enhance health. In this study, the oral health benefits of a number of food homogenates and high molecular mass and low molecular mass fractions were investigated. A comprehensive range of assays were performed to assess the action of these foods on the development of gingivitis and caries using bacterial species associated with these diseases. Both antigingivitis and anticaries effects were investigated by assays examining the prevention of biofilm formation and coaggregation, disruption of preexisting biofilms, and the foods' antibacterial effects. Assays investigating interactions with gingival epithelial cells and cytokine production were carried out to assess the foods' anti- gingivitis properties. Anti-caries properties such as interactions with hydroxyapatite, disruption of signal transduction, and the inhibition of acid production were investigated. The mushroom and chicory homogenates and low molecular mass fractions show promise as anti-caries and anti-gingivitis agents, and further testing and clinical trials will need to be performed to evaluate their true effectiveness in humans.
Subject(s)
Biofilms/drug effects , Cariostatic Agents/pharmacology , Gingivitis/microbiology , Plant Extracts/pharmacology , Shiitake Mushrooms/chemistry , Anti-Bacterial Agents/pharmacology , Bacteria/drug effects , Beer , Cell Adhesion/drug effects , Cell Aggregation/drug effects , Cell Line , Cichorium intybus/chemistry , Cytokines/metabolism , Fruit/chemistry , Humans , Hydroxyapatites , Signal Transduction , Tea/chemistryABSTRACT
The Jerusalem Balsam, a remedy based on an ethanolic extract of a herbal mixture, was formulated in 1719 in the pharmacy of the Saint Savior monastery in the old city of Jerusalem. Having gained fame, the Jerusalem Balsam was replicated and prepared in Europe. One can still find variations of the formula in current pharmacopoeias (B.P., 1998. The Stationary Office, London, p. 1510; Sweetman, S.C., Blake, P.S., McGlashan, J.M., Parsons, A.V., 2002. Martindale: The Extra Pharmacopeia, 33rd ed. Pharmaceutical Press, London, p. 1101). We report here, five different formulas, all referred to as "The Jerusalem Balsam". Three of those formulas were translated and two of these translations are presented in the text. A third one is available as Supplementary data online. As the formulas originate from different historical periods, the Jerusalem Balsam may be a good case study of the development of pharmaceutical formulations over a 250 years period. One of the formulas, found in a manuscript form in the archive of the monastery, contains four plants: olibanum (Boswellia spp.), myrrh (Commiphora spp.), aloe (Aloe sp.) and mastic (Pistacia lentiscus L.). We conducted pharmacological assays on this four-plant formula. It showed anti-inflammatory, as well as anti-oxidative, and anti-septic properties.
Subject(s)
Balsams/pharmacology , Animals , Anti-Infective Agents, Local/pharmacology , Anti-Inflammatory Agents/pharmacology , Antioxidants/pharmacology , Balsams/chemistry , Chemistry, Pharmaceutical , Humans , Israel , MiceABSTRACT
Previous studies have shown that macrophage receptors for oxidized LDL (OxLDL) recognize both the lipid and protein moieties, and that a monoclonal antibody against OxLDL, EO6, also recognizes both species. The present studies show directly that during LDL oxidation phospholipids become covalently attached to apolipoprotein B (apoB). After exhaustive extraction of lipids, apoB of native LDL contained 4 +/- 3 moles of phosphorus/mole protein. In contrast, apoB of OxLDL contained approximately 75 moles of phosphorus/mole protein. Saponification of this apoB released phosphorus, choline, and saturated fatty acids in a molar ratio of 1.0:0.98:0.84. When LDL was reductively methylated prior to oxidation, the amount of phospholipid covalently bound was reduced by about 80%, indicating that the phospholipids attach at lysine epsilon amino groups. Progressive decreases in the phospholipid associated with apoB of OxLDL decreased the ability of the protein to compete for binding to macrophage scavenger receptors and decreased its reactivity with antibody EO6. We postulate that some oxidized phospholipids containing fatty acid aldehydes at the sn-2 position bind to lysine residues of apoB while others remain unreacted within the lipid phase. This would account for the interchangeability of lipid and apolipoprotein of OxLDL with respect to receptor binding and antibody recognition.
Subject(s)
Apolipoproteins B/metabolism , Lipoproteins, LDL/metabolism , Phospholipids/metabolism , Receptors, Immunologic/metabolism , Animals , Apolipoproteins B/chemistry , Female , Humans , In Vitro Techniques , Ligands , Macrophages, Peritoneal/metabolism , Mice , Oxidation-Reduction , Phosphorus/metabolism , Receptors, Scavenger , Thiobarbituric Acid Reactive Substances/metabolismABSTRACT
OBJECTIVE: The purpose of this animal study was to determine whether IB-367, an antimicrobial peptide, is able to ameliorate oral mucositis by reducing microflora densities on the mucosal surfaces of the mouth. STUDY DESIGN: Oral mucositis was induced in hamsters by intraperitoneal injection of 5-fluorouracil followed by superficial abrasion of the buccal mucosa. A test formulation was applied topically to the buccal mucosa 5 or 6 times per day starting 6 to 8 hours before abrasion. RESULTS: Mucositis scores were significantly lower (P < .05) in hamsters given formulations containing 0.5 or 2.0 mg/mL of IB-367 than in placebo-treated controls. Treatment with IB-367 produced a more than 100-fold reduction in oral microflora densities. In a second experiment, treatment of hamsters with a formulation containing IB-367 at 0.12, 0.5 or 2.0 mg/mL resulted in a dose-dependent reduction in mucositis severity. CONCLUSION: The results indicate that reduction of local microflora densities through use of IB-367 may improve clinical outcomes in patients at risk for the development of oral mucositis.
Subject(s)
Anti-Infective Agents, Local/therapeutic use , Mouth Mucosa/microbiology , Proteins/therapeutic use , Stomatitis/drug therapy , Animals , Anti-Infective Agents, Local/administration & dosage , Antimicrobial Cationic Peptides , Bacillus/drug effects , Colony Count, Microbial , Cricetinae , Dose-Response Relationship, Drug , Drug Evaluation, Preclinical , Escherichia coli/drug effects , Fluorouracil , Male , Mesocricetus , Pasteurella/drug effects , Peptide Fragments/administration & dosage , Peptide Fragments/therapeutic use , Peptides , Proteins/administration & dosage , Proteus mirabilis/drug effects , Statistics, Nonparametric , Stomatitis/chemically induced , Stomatitis/microbiology , Streptococcus/drug effectsABSTRACT
The aim was to investigate the effect of honey on the microhardness of enamel in normal and xerostomic patients. Normal subjects and patients who were xerostomic after neck irradiation, wearing prosthetic appliances with slabs of human enamel inserted, were asked to consume a single teaspoonful of pure honey, pH 3.9. Measurements of the saliva pH were taken before, during and after a 5 min exposure to the honey. The pH of the honey-saliva mixtures decreased significantly from about 6 to 4 in both groups, returning to the baseline pH after the mixture was swallowed. The initial microhardness of the surface of the enamel slabs decreased significantly after consumption of a teaspoonful of the honey in the subjects with a regular saliva flow, whereas in the irradiated dry-mouth patients, no enamel microhardness decrease occurred. The supposed solubility-reducing factor present in honey which, according to the literature remains active in the absence of saliva, but will be inactivated by salivary enzymes, gives some support to the hypothesis that honey is less cariogenic in dry-mouth subjects. The absence of adequate controls in the present study prevents the investigation of how specific this effect is to honey.
Subject(s)
Dental Enamel/ultrastructure , Honey , Xerostomia/pathology , Adult , Calcium/analysis , Cariogenic Agents/adverse effects , Dental Enamel Solubility , Female , Fluorides/analysis , Hardness , Head and Neck Neoplasms/radiotherapy , Honey/adverse effects , Honey/analysis , Humans , Hydrogen-Ion Concentration , Male , Middle Aged , Phosphorus/analysis , Radiation Injuries/etiology , Saliva/enzymology , Saliva/metabolism , Saliva/physiology , Secretory Rate , Xerostomia/etiology , Xerostomia/physiopathologyABSTRACT
Probucol is a powerful inhibitor of atherosclerosis in a number of animal models. However, it is unknown whether this is due to the strong antioxidant protection of low density lipoprotein (LDL), to antioxidant effects in the artery wall, or to cellular effects not shared by other antioxidants. To investigate whether murine models are suitable to study the antiatherogenic mechanisms of probucol, three experiments following different protocols were carried out in 135 male and female LDL receptor-deficient (LDLR-/-) mice. Treatment groups received a high (0.5%) or low (0.025%) dose of probucol, or low-dose probucol plus a high dose (0.1%) of vitamin E for periods ranging from 6 to 26 weeks. In all experiments, probucol strongly protected LDL against ex vivo oxidation (lag times exceeding 1400 min in 0.5% probucol-treated mice). Treatment with 0.5% probucol significantly lowered both HDL-cholesterol and plasma apolipoprotein (apo)A-I concentrations. In all three experiments, treatment with 0.5% probucol consistently increased the size of lesions in the aortic origin, from 1.3-fold (n.s.) to 2.9-fold (P < 0.05) in female mice and from 3.6- to 3.7-fold in males (P < 0.001). Even treatment with 0.025% probucol increased atherosclerosis 1.6-fold in male mice (P < 0.01). Addition of the high dose of vitamin E did not attenuate the pro-atherogenic effect of 0.025% probucol. In conclusion, probucol not only failed to decrease but actively increased atherogenesis in LDLR-/- mice in a dose-dependent manner, even though it provided a very strong antioxidant protection of LDL. This suggests that the reduction of atherosclerosis observed in other animal models is due to intracellular effects of probucol not found in mice, to differences in the metabolism of probucol, and/or to an overriding atherogenic effect of the decrease in HDL in murine models.
Subject(s)
Anticholesteremic Agents/pharmacology , Arteriosclerosis/blood , Lipoproteins, LDL/blood , Probucol/pharmacology , Receptors, LDL/physiology , Animals , Anticholesteremic Agents/blood , Cholesterol, Dietary/blood , Cholesterol, Dietary/pharmacology , Female , Lipoproteins, HDL/blood , Male , Mice , Mice, Inbred C57BL , Probucol/blood , Receptors, LDL/blood , Vitamin E/blood , Vitamin E/pharmacologyABSTRACT
Dental caries and periodontal diseases are chronic infectious diseases caused by oral bacteria. Local sustained release delivery systems extend the time in which the drug is present in the oral cavity, thus enhancing its therapeutic potential while reducing its side effects. Amine-fluorides (AmF) are known anticaries agents and have recently been found to have an antibacterial effect against periodontal pathogens and caries-associated bacteria. The purpose of this in vitro study was to assess the antimicrobial activity of a local sustained release device (LSRD) containing AmF on Streptococcus sobrinus 6715. LSRD was prepared from an ethylcellulose matrix containing AmF. Release kinetics of AmF from the LSRD was measured simultaneously with its antimicrobial activity. The organic amine and the fluoride were released in different kinetics profiles: The fluoride was released faster than the organic amine. The antimicrobial activity of AmF was measured on planktonic bacteria in solution and on bacteria as part of experimental dental plaque. During a 10-day period, the concentration of the released AmF was above its MIC and no bacterial growth was observed. Bacterial counts in the dental plaque were reduced by 1 to 2 log units. Hence, the LSRD containing AmF has the potential to serve as a medicament in prevention and treatment of dental caries and periodontal diseases.
Subject(s)
Anti-Infective Agents, Local/pharmacology , Fluorides/pharmacology , Anti-Infective Agents, Local/pharmacokinetics , Bacterial Infections/metabolism , Delayed-Action Preparations , Fluorides/pharmacokinetics , Microbial Sensitivity Tests , Mouth Diseases/drug therapy , Mouth Diseases/metabolism , Mouth Diseases/microbiologyABSTRACT
Protegrin-1 (PG-1) is a cysteine-rich, 18-residue beta-sheet peptide isolated from porcine leukocytes with antimicrobial activity against a broad range of microorganisms. The MICs of PG-1 against representative gram-positive and gram-negative bacteria ranged from 0.12 to 2 microg/ml. At these levels, PG-1 was rapidly bactericidal in vitro, reducing the number of viable CFU of either methicillin-resistant Staphylococcus aureus (MRSA) or Pseudomonas aeruginosa by more than three log units in less than 15 min. Resistance to PG-1 did not develop after 11 subculturings of P. aeruginosa or 18 subcultures of MRSA in Mueller-Hinton broth containing PG-1 at one-half the MIC. Under similar conditions of serial passage, the MICs of norfloxacin and gentamicin against P. aeruginosa increased 10 and 190 times, respectively. Similarly, the MIC of norfloxacin against MRSA increased 85 times. Immunocompetent mice inoculated intraperitoneally (i.p.) with P. aeruginosa or S. aureus exhibited 93 to 100% mortality in the vehicle control group compared with 0 to 27% mortality in animals that received a single i.p. injection of PG-1 (0.5 mg/kg of body weight). Mice inoculated with S. aureus by intravenous (i.v.) injection and dosed 0 to 60 min later with a single i.v. injection of PG-1 (5 mg/kg) had a mortality of 7 to 33%, compared to a mortality of 73 to 93% in the vehicle controls. In leukopenic mice inoculated i.v. with vancomycin-resistant Enterococcus faecium, mortality was 87% in the vehicle control group and 33% in animals that received a single i.v. injection of PG-1 (2.5 mg/kg). Taken together, these data indicate that PG-1 has potential for use as an antimicrobial agent in the treatment of local or systemic infections caused by clinically relevant pathogens.
Subject(s)
Anti-Infective Agents/therapeutic use , Bacteria/drug effects , Bacterial Infections/drug therapy , Proteins/therapeutic use , Animals , Anti-Bacterial Agents , Anti-Infective Agents/blood , Antimicrobial Cationic Peptides , Bacteria/metabolism , Bacterial Infections/blood , Candida albicans/drug effects , Drug Evaluation, Preclinical , Escherichia coli/drug effects , Male , Mice , Mice, Inbred ICR , Microbial Sensitivity Tests , Proteins/metabolism , Staphylococcus aureus/drug effectsABSTRACT
The oxidative modification of low density lipoproteins (LDL) by arterial wall cells is thought to contribute to atherogenesis. Monocyte/macrophages, among other arterial wall cells, oxidatively modify LDL to a form that is recognized by scavenger/oxidized LDL receptors. It has recently been suggested that LDL binding to the LDL receptor (B/E receptor) is essential for macrophage-mediated oxidation of LDL. In the present study, we compared the ability of resident peritoneal macrophages from LDL-R-deficient (LDLR-/-) mice to oxidize LDL with that of resident peritoneal macrophages from C57B6 mice. The LDLR-/- macrophages oxidized LDL at least as rapidly as did the C57B6 macrophages both in F-10 medium and in Dulbecco's modified Eagle's medium supplemented with 1 microM copper (DMEM-Cu2+). Studies were also conducted to examine the effect of preincubation of LDLR-/- and C57B6 macrophages with 10% lipoprotein-deficient serum (LPDS), which up-regulates LDL receptors, or with acetylated LDL (Ac-LDL), which increases cellular cholesterol and down-regulates LDL receptors. Preincubation with 10% LPDS had no significant effect on subsequent LDL oxidation by either type of cells in F10 medium, but the C57B6 cells did show a small (18%) but significant increase in LDL oxidation in DMEM-Cu2+. Preincubation with 50 micrograms/ml Ac-LDL in F10 medium had no effect on LDL oxidation by either LDLR-/- or C57B6 macrophages. Preincubation with 100 micrograms/ml Ac-LDL had no effect on subsequent LDL oxidation by C57B6 cells but, unexpectedly, caused a modest (26%) fall in LDL oxidation by the receptor-negative cells. Using DMEM-Cu2+ medium, preincubation with Ac-LDL reduced LDL oxidation substantially (50-66%) but the effect was just as great in LDL-R negative cells (59-66%) as in C57B6 cells (50-58%), suggesting that the effect is not due to changes in LDL receptor density. It may be related somehow to the Ac-LDL-induced increase in cell cholesterol content. The data demonstrate that the absence of LDL receptors does not reduce the ability of macrophages to oxidize LDL and that LDL binding to LDL receptors is not an essential requirement for macrophage oxidation of LDL.
Subject(s)
Lipoproteins, LDL/metabolism , Macrophages, Peritoneal/metabolism , Receptors, LDL/metabolism , Animals , Cholesterol/metabolism , In Vitro Techniques , Kinetics , Male , Mice , Mice, Inbred C57BL , Mice, Mutant Strains , Oxidation-Reduction , Receptors, LDL/deficiency , Receptors, LDL/geneticsABSTRACT
The hypothesis that oxidative modification of low density lipoprotein contributes to the progression of atherosclerosis is supported by an impressive body of in-vitro findings and by persuasive results in animal models of atherosclerosis. The hypothesis was originally proposed specifically to account for foam cell formation but oxidation of LDL has now been shown to confer on it a long list of new biological properties any one of which could in principle enhance its atherogenicity. The relative importance of these altered biological properties in vivo remains uncertain. Whatever the precise mechanisms, we know that antioxidants can slow the atherogenic process in several experimental models, including LDL-receptor-deficient rabbits, cholesterol-fed rabbits, and cholesterol-fed non-human primates. Of 18 published studies, 13 have given strongly positive results, the rate of progression of lesions being reduced by 50-80%; 2 have yielded marginally positive results; and 3 have been negative (see ref 3 for references). Furthermore, the fact that four different antioxidant compounds have been used--probucol, butylated hydroxytoluene, N,N'-diphenyl-phenylenediamine, and vitamin E--supports the conclusion that they are working via the property they all share, namely, their antioxidant potential.
Subject(s)
Antioxidants/therapeutic use , Arteriosclerosis/drug therapy , Clinical Trials as Topic , Animals , Coronary Disease/drug therapy , Drug Evaluation, Preclinical , HumansABSTRACT
There is strong experimental evidence that oxidized low density lipoprotein (Ox-LDL) plays an important role in atherosclerosis. However, the mechanisms by which Ox-LDL is formed in vivo are unknown. To test whether 15-lipoxygenase (15-LO) could play a role in oxidation of LDL by cells, we expressed 15-LO activity in murine fibroblasts, which do not normally have 15-LO activity, and tested their ability to modify LDL. Using a retroviral vector, we prepared fibroblasts that expressed 2- to 20-fold more 15-LO activity than control fibroblasts infected with a vector containing beta-galactosidase (lacZ). Compared with LDL incubated with lacZ cells, LDL incubated with 15-LO-containing cells were enriched with lipid hydroperoxides. When these LDL samples were subsequently subjected to oxidative stress, they were more susceptible to further oxidative modification, as judged by increased conjugated diene formation and by increased ability to compete with 125I-Ox-LDL for uptake by macrophages. These findings establish that cellular 15-LO can contribute to oxidative modification of LDL, but the quantitative significance of these findings to the in vivo oxidation of LDL remains to be established.
Subject(s)
Arachidonate 15-Lipoxygenase/metabolism , Lipid Peroxides/metabolism , Lipoproteins, LDL/metabolism , Animals , Arachidonate 15-Lipoxygenase/biosynthesis , Blotting, Northern , Cell Line , Cells, Cultured , DNA, Complementary , Fibroblasts/metabolism , Gene Expression , Genetic Vectors , Humans , Kinetics , Macrophages, Peritoneal/metabolism , Mice , Polymerase Chain Reaction , RNA, Messenger/analysis , RNA, Messenger/biosynthesis , Recombinant Proteins/biosynthesis , Recombinant Proteins/metabolism , Retroviridae , Transfection , beta-Galactosidase/biosynthesis , beta-Galactosidase/metabolismABSTRACT
We report the results of feeding oleate- or linoleate-enriched diets for 8 wk to mildly hypercholesterolemic subjects and the resulting alterations in composition and functional properties of their plasma LDL and HDL. LDL isolated from subjects on oleate-enriched diets was less susceptible to copper-mediated oxidation, as measured by conjugated diene and lipid peroxide formation, and less susceptible to LDL-protein modification, as evidenced by reduced LDL macrophage degradation after copper- or endothelial cell-induced oxidation. For all subjects, the percentage of 18:2 in LDL correlated strongly with the extent of conjugated diene formation (r = 0.89, P < 0.01) and macrophage degradation (r = 0.71, P < 0.01). Oxidation of LDL led to initial rapid depletion of unsaturated fatty acids in phospholipids followed by extensive loss of unsaturated fatty acids in cholesteryl esters and triglycerides. Changes in HDL fatty acid composition also occurred. However, HDL from both dietary groups retained its ability to inhibit oxidative modification of LDL. This study demonstrates that alterations in dietary fatty acid composition can effectively alter the fatty acid distribution of LDL and HDL in hypercholesterolemic subjects and that susceptibility to LDL oxidation is altered by these changes. Substitution of monounsaturated (rather than polyunsaturated) fatty acids for saturated fatty acids in the diet might be preferable for the prevention of atherosclerosis.
Subject(s)
Dietary Fats, Unsaturated/pharmacology , Hypercholesterolemia/metabolism , Linoleic Acids/pharmacology , Lipoproteins, LDL/metabolism , Oleic Acids/pharmacology , Adult , Fatty Acids/analysis , Female , Humans , Linoleic Acid , Lipoproteins, HDL/metabolism , Lipoproteins, LDL/analysis , Macrophages/metabolism , Male , Middle Aged , Oleic Acid , Oxidation-ReductionABSTRACT
Oxidized low-density lipoprotein (LDL) is more atherogenic than native LDL. The initial step in the oxidation is the peroxidation of polyunsaturated fatty acids. Thus, decreasing the concentration of polyunsaturated fatty acids should reduce the susceptibility of LDL to oxidation. Therefore, we tested the possibility that diets enriched in oleate might result in LDL that is less susceptible to oxidative modification. LDL isolated from subjects consuming an oleate-enriched diet, compared with LDL from subjects on a linoleate-enriched diet, contained significantly more oleate (28.7% vs 11.5%) and less linoleate (31.9% vs 50.9%). Generation of conjugated dienes was significantly lower in the LDL from the oleate group. Most important, after incubation with endothelial cells, LDL from the oleate group underwent less degradation by macrophages. These studies demonstrate the feasibility of altering the diet in a way that will not raise LDL cholesterol concentrations and yet will decrease the susceptibility of LDL to oxidative modification.
Subject(s)
Dietary Fats, Unsaturated/administration & dosage , Lipoproteins, LDL/metabolism , Oleic Acids/administration & dosage , Adult , Body Weight , Cholesterol/blood , Cholesterol, HDL/blood , Cholesterol, LDL/blood , Diet Records , Fatty Acids/analysis , Helianthus , Humans , Linoleic Acid , Linoleic Acids/administration & dosage , Lipid Peroxidation , Lipoproteins, LDL/chemistry , Oxidation-Reduction , Patient Compliance , Plant Oils/administration & dosage , Random Allocation , Sunflower OilABSTRACT
Oxidative modification of low density lipoprotein (LDL) enhances its potential atherogenicity in several ways, notably by enhancing its uptake into macrophages. In vivo studies in the rabbit show that inhibition of LDL oxidation slows the progression of atherosclerotic lesions. In the present studies, rabbits were fed either a newly developed variant sunflower oil (Trisun 80), containing more than 80% oleic acid and only 8% linoleic acid, or conventional sunflower oil, containing only 20% oleic acid and 67% linoleic acid. LDL isolated from the plasma of animals fed the variant sunflower oil was highly enriched in oleic acid and very low in linoleic acid. These oleate-rich LDL particles were remarkably resistant to oxidative modification. Even after 16-hr exposure to copper-induced oxidation or 24-hr incubation with cultured endothelial cells, macrophage uptake of the LDL was only marginally enhanced. The results suggest that diets sufficiently enriched in oleic acid, in addition to their LDL-lowering effect, may slow the progression of atherosclerosis by generating LDL that is highly resistant to oxidative modification.
Subject(s)
Arteriosclerosis/prevention & control , Dietary Fats , Endothelium, Vascular/metabolism , Lipid Peroxidation , Lipoproteins, LDL/metabolism , Oleic Acids/metabolism , Animals , Biological Transport , Cells, Cultured , Copper/pharmacology , Fatty Acids/analysis , Kinetics , Lipoproteins, LDL/blood , Lipoproteins, LDL/isolation & purification , Macrophages/metabolism , Mice , Oleic Acid , Plant Oils , Rabbits , Sunflower OilABSTRACT
The effectiveness of core decompression and bone grafting with and without electrical stimulation was investigated in patients with avascular necrosis (AVN) of the femoral head. One hundred sixteen hips with AVN had decompression and grafting; 74 were also treated with direct current (DC). The DC stimulation was via a coil inserted directly into the femoral head. These were compared to 55 hips with AVN treated nonoperatively. Hips treated with electrical stimulation showed less roentgenographic progression and achieved a better clinical score than hips treated with decompression and grafting alone. Both groups had a significantly lower incidence of arthroplasty than the nonoperated controls. One patient developed a pulmonary embolus, but there were no fractures or other complications. Decompression and grafting are safe and reasonably effective in retarding the progression of AVN. Supplemental electrical stimulation seems to improve the results even further.
Subject(s)
Bone Transplantation , Electric Stimulation Therapy , Femur Head Necrosis/surgery , Arthroplasty , Double-Blind Method , Femur Head Necrosis/diagnostic imaging , Femur Head Necrosis/physiopathology , Follow-Up Studies , Humans , Postoperative Complications , Prospective Studies , Radiography , Random AllocationABSTRACT
Castrated male Sprague Dawley rats were subjected to various capacitively coupled electrical fields for six and eight weeks at two and 4.5 months after castration, respectively, with pairs of electrodes that were located paraspinally on the surface of the skin dorsally at the eleventh thoracic and fourth lumbar levels. When the animals were killed, dry and ash weights per unit of volume (apparent density), elastic modulus, ultimate stress, work to failure, trabecular area fraction, and mean trabecular width were determined for selected vertebrae. The results indicated that a sixty-kilohertz, 100-microampere signal (a calculated current density of five microamperes root-mean-square per square centimeter and a field of twelve millivolts root-mean-square per centimeter) significantly reversed the castration-induced osteoporosis in the lumbar vertebrae and restored bone mass per unit of volume in rats that had been stimulated for eight weeks after castration.
Subject(s)
Electric Stimulation Therapy , Orchiectomy , Osteoporosis/therapy , Animals , Electric Stimulation Therapy/instrumentation , Electric Stimulation Therapy/methods , Lumbar Vertebrae/pathology , Male , Organ Size , Osteoporosis/etiology , Osteoporosis/pathology , Rats , Rats, Inbred Strains , Thoracic Vertebrae/pathology , Time FactorsABSTRACT
Previous studies from this laboratory have shown that oxidative modification of low-density lipoprotein (LDL) causes it to be recognized by the scavenger receptor of the macrophage. Consequently, the rate of degradation of oxidized LDL by macrophages can be 3 to 10 times that of native LDL. Antioxidants, such as probucol, are highly effective in preventing the oxidative modification of LDL. Our recent studies show that probucol treatment of LDL receptor-deficient Watanabe heritable hyperlipidemic (WHHL) rabbits selectively inhibits the degradation of LDL in fatty streak lesions (which are rich in macrophage-derived foam cells) without inhibiting degradation in nonlesioned areas (where degradation is predominantly in smooth muscle cells, which do not express the scavenger receptor). Furthermore, the rate of progression of lesions in probucol-treated animals was significantly slower than in a lovastatin-treated group maintained at equal total plasma cholesterol levels. These results strongly suggest that probucol, through an antioxidant activity not necessarily related to its ability to lower plasma cholesterol levels, can slow the progression of the foam-cell-rich fatty streak lesion of atherosclerosis.
Subject(s)
Foam Cells/drug effects , Macrophages/drug effects , Phenols/pharmacology , Probucol/pharmacology , Animals , Arteriosclerosis/etiology , Arteriosclerosis/metabolism , Arteriosclerosis/prevention & control , Depression, Chemical , Drug Evaluation, Preclinical , Foam Cells/metabolism , Hyperlipidemias/drug therapy , Hyperlipidemias/genetics , Hyperlipidemias/metabolism , Lipoproteins, LDL/metabolism , Lovastatin/therapeutic use , Oxidation-Reduction/drug effects , Probucol/therapeutic use , RabbitsABSTRACT
To date, there is no completely satisfactory method for the treatment of osteonecrosis of the femoral head. "Conservative" management leads to a high failure rate, and surgical results have been inconsistent and disappointing. The study described in this article seeks to evaluate the role of electrical stimulation in conjunction with decompression and bone grafting. A total of 82 hips have been included to date, of which 42 with a minimum follow-up of 1 year have been evaluated. Pain relief and improved function have been noted in the majority of hips operated on, both with and without electrical stimulation. Careful radiologic assessment using a comprehensive new method of evaluation has shown some degree of progression in the majority of cases, however. No effects of electrical stimulation per se have been demonstrated to date. It must be emphasized that this is a preliminary report with a minimum follow-up of 1 year. Final conclusions await the completion of the study, when all patients have been followed for a minimum of 3 years.